Ex parte HERGENROTHER et al. - Page 7




          Appeal No. 96-0819                                                          
          Application No. 08/146,696                                                  


          guide.  In this regard, note the relatively large difference                
          between the upper limit of Kendrick's preferred range (50,000)              
          and the lower limit of the claimed range (at least about                    
          100,000).  On these facts, we find that appellants suggest the              
          desirability of a number average molecular weight of at least               
          about 100,000, but the cited prior art does not.                            
               The examiner argues that Kendrick is "generic to any                   
          molecular weight" (Answer, page 4, lines 12 and 13); that                   
          Kendrick encompasses block copolymers having a molecular                    
          weight within appellants' claimed range; and that Kendrick                  
          directs a person having ordinary skill to prepare a block                   
          copolymer having any molecular weight.  However, we are not                 
          aware of any such                                                           
          per se rule of obviousness whereby a generic teaching with                  
          respect to molecular weight is sufficient to reach appellants'              
          specific claim limitation.  On the contrary, every case,                    
          particularly those raising the issue of obviousness under                   
          § 103, must necessarily be decided on its own facts.  Cf. In                
          re Jones, 958 F.2d 347, 350, 21 USPQ2d 1941, 1943 (Fed. Cir.                
          1992) (court declines to extract from Merck & Co. v. Biocraft               
          Labs. Inc., 874 F.2d 804, 806-09, 10 USPQ2d 1843, 1845-48                   
                                         -7-                                          





Page:  Previous  1  2  3  4  5  6  7  8  9  10  Next 

Last modified: November 3, 2007